Nano Retina Announces Preliminary Results for First-in-Human Implantation of Its NR600 Artificial Retina Device
HERZLIYA, Israel, March 30, 2020 /PRNewswire/ — Nano Retina Ltd., developer of the NR600, an artificial retina device that mimics the natural physiological processes of the human eye and restores functional vision to persons blinded by retinal degenerative diseases, including age-related macular degeneration and retinitis pigmentosa, today reported preliminary results for First-in-Human implantations of its artificial retina device in March 2020.
As part of a European multicenter clinical trial enrolling up to 20 patients for the purpose of obtaining CE approval of the NR600, the first two patients, blinded by retinitis pigmentosa, have undergone the minimally invasive procedure to implant the device. The procedures were both performed in the Department of Ophthalmology of the University Hospital Leuven, Belgium, by Professor Peter Stalmans, one of Europe’s leading retina specialists.
Professor Stanislao Rizzo will deliver the Conference Keynote Lecture ‘The restless fight against inherited blindness’ during the Gisbert Richard lecture on Friday, 2 October at 10:15 CEST. Professor Rizzo is an investigator in the NR600 Clinical Trial and will discuss the NR600 during his lecture.
Professor Peter Stalmans of UZ Leuven, Belgium, will speak at the RETINATECH: Where Technology Meets Surgery Symposium on Friday, 2 October from 14:45 to 15:30. He will present first reported clinical results from end-stage RP patients implanted with the NR600, an innovative 3D-neural interface retinal prosthesis.
PRO Retina Germany
Professor Dov Weinberger will present on 2 October from 16:00 to 17:00 on the NR600 retina implant from Nano Retina.
American Academy of Ophthalmology AAO 2020